nizatidine

H2-receptor antagonist

Oral: 150–600 mg dailyIV: 300–480 mg daily

Molecular weight :331.5

%Protein binding :35

%Excreted unchanged in urine : 60

Volume of distribution (L/kg) :0.8–1.3

half-life – normal/ESRD (hrs) :1–2/3.5–11

20 to 50 : 150–300 mg daily <20 150 mg daily

CAPD :Not dialysed. Dose as in GFR<20 mL/min

HD :Not dialysed. Dose as in GFR<20 mL/min

HDF/high flux :Unknown dialysability. Dose as in GFR<20 mL/min

CAV/VVHD :Unknown dialysability. Dose as in GFR<20 mL/min

Potentially hazardous interactions with other drugs

Antifungals: absorption of itraconazole and ketoconazole reduced

–

Oral, IV

Continuous

: Dilute 300 mg in 150 mL. Rate 10 mg/hour. Bolus: Dilute 100 mg in 50 mL and give over 15 minutes

Compatible with sodium chloride 0.9% or glucose 5%.To maintain gastric pH ≥4, a continuous infusion of 10 mg/hour is recommended

The effect of haemodialysis is unproven. It is not expected to be efficient since nizatidine has a large volume of distribution.